Treatment approaches combining cytostatic drugs with the oncolytic parvovirus H-1 increase cytotoxic effects in cell culture models of highly malignant pediatric brain tumors

Oncolytic virotherapy with Parvovirus H-1 (H-1PV) represents a new therapeutic approach investigated in a phase I/IIa clinical trial recruiting adult glioblastoma patients. In pediatric neurooncology there is also an urgent need for new therapeutic options. In vitro H-1PV has already been demonstrated to induce cytotoxic effects in medulloblastoma and pediatric glioblastoma. However, the application of combination therapies is inevitable to avoid the development of resistant subclones of cancer cells. Here we analyzed, whether H-1PV is able to increase the cytotoxic efficacy of conventional cytostatic treatment…